1 September 2024

Starpharma commences pivotal phase 3 VivaGel trials for bacterial vaginosis treatment

Melbourne Australia:  Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the commencement of two concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.

Key Points:

  • Two pivotal phase 3 trials launched for the treatment of bacterial vaginosis (BV)
  • Special Protocol Assessment (SPA) already received from the FDA which confirms the design of the planned studies is acceptable to support a New Drug Application (NDA) and marketing approval of VivaGel®
  • Trials to be completed in 2012
  • Preparation of NDA submission and out-licensing discussions to follow

Download ASX Announcement ( pdf file, 193kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.